Results 81 to 90 of about 38,631 (238)

A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction

Journal of Cardiovascular Pharmacology and Therapeutics, 2018
Background: Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together with nitrates, synergistic effects that enhance hypotensive ...
Robert A. Kloner, Paul Goggin, Irwin Goldstein, Geoffrey Hackett, Michael G. Kirby, Ian Osterloh, John D. Parker, Richard Sadovsky   +7 more
openaire   +2 more sources

Responsive nitric oxide‐releasing antibacterial materials for biofilm‐associated infections: Mechanisms, design strategies, and applications

Responsive Materials, EarlyView.
This review summarizes the recent progress in responsive NO‐releasing materials and their applications in biofilm‐associated infectious diseases. The design principles and response mechanisms are given to provide inspiration toward the future development of multi‐responsive NO‐releasing materials.
Wenyue Sun, Meiqi Li, Di Nan, Jiaqi Zhao, Yu Chen, Yao Gao, Shichen Zhang, Kirsten L. Van Landuyt, Manlin Qi   +8 more
wiley   +1 more source

Tadalafil in the treatment of erectile dysfunction

Therapeutics and Clinical Risk Management, 2008
Robert M Coward, Culley C CarsonDivision of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USAAbstract: The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors ...
Robert M Coward, Culley C Carson
doaj  

TcALS knockdown accelerates metamorphosis via insulin signaling in Tribolium castaneum

Insect Science, EarlyView.
RNAi silencing of TcALS accelerates larva‐to‐pupa metamorphosis in Tribolium castaneum. Abstract Insect metamorphosis is an evolutionary adaptation precisely regulated by nutritional and hormonal cues. The red flour beetle Tribolium castaneum, a major stored‐product pest, serves as an excellent model for studying this process.
Min Li, Jie Chen, Zi‐Ye Wang, Fei‐Feng Wang, Lu‐Lu Dong, Jun Pan, Min‐Er Li, Lin Yu, Wen Sang   +8 more
wiley   +1 more source

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

Research and Reports in Urology, 2013
Mauro Gacci,1 Matteo Salvi,1 Arcangelo Sebastianelli,1 Linda Vignozzi,2 Giovanni Corona,3 Kevin T McVary,4 Steven A Kaplan,5 Mario Maggi,2 Marco Carini,1 Matthias Oelke6 1Department of Urology, University of Florence, Florence, 2Sexual Medicine and ...
Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT, Kaplan SA, Maggi M, Carini M, Oelke M   +9 more
doaj  

The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Urology Research and Practice, 2019
Phosphodiesterase type-5 (PDE-5) inhibitors are approved as the first line of therapy for the treatment of erectile dysfunction. However, different studies have been performed to study the use of these agents in other areas of urology.
Mehmet UMUL, Tekin Ahmet SEREL
doaj   +1 more source

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study

Australasian Journal of Dermatology, EarlyView.
ABSTRACT This Australian retrospective cohort analysis of 1977 patients investigates and expands on correlates of telangiectasia in systemic sclerosis to determine whether this cutaneous sign is a potential surrogate marker for disease progression and prognosis.
Vivien Wai Yun Lai, Dylan Hansen, Maryam Tabesh, Jessica Fairley, Laura Ross, Nava Ferdowsi, Gene‐Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, Lauren V. Host, Jennifer Walker, Gabor Major, Susanna Proudman, Wendy Stevens, Mandana Nikpour, Amanda M. Saracino   +15 more
wiley   +1 more source

Predictive value of systemic inflammatory response index in patients with erectile dysfunction on tadalafil unresponsive patients

The Aging Male
Background Erectile dysfunction (ED) is a common disorder that significantly impacts quality of life, and phosphodiesterase type 5 inhibitors (PDE5is) such as tadalafil are one of the primary treatments.
Resul Sobay
doaj   +1 more source

AB030. Evolution of phosphodiesterase type 5 inhibitors [PDF]

Transl Androl Urol, 2016
After launching of sildenafil citrate, the last invention of 20(th) century, in 1998, oral phosphodiesterase type 5 (PDE5) inhibitor has been established as first line treatment of erectile dysfunction and shift new paradigm of diagnosis and treatment of erectile dysfunction.
europepmc   +3 more sources

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source